VAERS ID: 1000256

Description

Deterioration in general condition; Vigilance reduction; Acute kidney failure; Fall; Epilepsy; Hypercalcemic crisis; This is a spontaneous report from a non-contactable physician downloaded from the Medicines Agency (MA) WEB. The regulatory authority report number is DE-DCGMA-21187620. A female patient of an unspecified age received BNT162B2 (COMIRNATY), intramuscular on 09Jan2021 as first 0.3 mL, single for immunization. The patient's medical history noted, CT Throrax-Abdomen noted thickened esophagus on an unspecified date. Concomitant medication included dimeticone, silicon dioxide, colloidal (LEFAX [DIMETICONE;SILICON DIOXIDE, COLLOIDAL]), calcium glubionate (CALCIUM-SANDOZ [CALCIUM GLUBIONATE]), colecalciferol (DEKRISTOL), torasemide (MANUFACTURER UNKNOWN), candesartan (MANUFACTURER UNKNOWN), prednisolone (MANUFACTURER UNKNOWN), tapentadol hydrochloride (PALEXIA), macrogol (LAXOFALK), pantoprazole sodium sesquihydrate (MANUFACTURER UNKNOWN), bisacodyl (DULCOLAX) , metamizole (MANUFACTURER UNKNOWN). The patient experienced vigilance reduction, acute kidney failure, fall, epilepsy, hypercalcemic crisis on 13Jan2021; the patient also experienced deterioration in general condition on 14Jan2021. The events were serious as they involved hospitalization and lead to death. The patient underwent lab tests and procedures on an unspecified date, which included blood calcium: 2.4 mmol/l; blood creatinine: 2.8 mg/dl; Computerised tomogram (CT) Throrax-Abdomen: thickened esophagus; parathyroid hormone: 9.0 ng/ml. Details were as follows: after vaccination, the patient developed general physical condition abnormal and fall and acute renal failure and hypercalcaemia and vigilance decreased and epilepsy, lasting for eight days. The patient is dead. A diagnosis was confirmed by blood creatinine result: (2.8, unit: mg/dl), calcium (result: 2.4, unit: mmol/l). The death cause was reported as acute renal failure. After vaccination, the patient also developed vigilance decreased and hypercalcaemia and seizure cerebral and acute renal failure, lasting for unknown. The patient was hospitalized, and was dead. CT-Thorax-Abdomen without contrast medium noted possible esophageal carcinoma. Notes in the patient history noted CT Throrax-Abdomen noted thickened esophagus. Disturbance in attention, acute kidney injury, epilepsy, and hypercalcaemia were reported with stop date 20Jan2021 (also reported as with fatal outcome). The causality information for BNT162B2 for all the events per attending physician/ was reported as D. Unclassifiable. Referenced "dekristol 1000 palexia 50". The reporter's commented that measures: infusion therapy to lower calcium, prednisone IV. (50mg / d), calcitonin 100 IU 2x subcutaneous. A sufficiently reliable, alternative cause for the above entities could not be found. The patient died on 20Jan2021. It was not reported if an autopsy was performed. No follow-up attempts are possible; information about batch/lot number cannot be obtained.; Reported Cause(s) of Death: Acute renal failure